The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer
Open Access
- 1 September 2024
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 17, 755-763
Abstract
Objective: PIK3CA-mutant non-small-cell lung cancer (NSCLC) is associated with other genetic mutations and may influence treatment strategies and clinical outcomes. We aimed to characterize PIK3CA mutations co-occurring with several major driver mutations using data from published cohorts and our medical center. Materials and Methods: We analyzed NSCLC patients harboring PIK3CA mutations from The Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering (MSK) databases and retrospectively identified NSCLC patients with PIK3CA-mutants at a single medical center from our electronic records. The Log rank test was used to determine the association between PIK3CA mutations and overall survival (OS) in NSCLC patients. Results: Common hotspot mutations in PIK3CA were found in exon 9 (c.1633G > A, E545K, and c.1624G > A, E542K) and exon 20 (c.3140A > G, H1047R) in all cohorts. Co-occurring mutations of PIK3CA with EGFR, KRAS, and TP53 have been frequently observed in patients with NSCLC, with different percentages in these datasets generated by different background. PIK3CA mutations were observed to be significantly associated with poor OS in lung adenocarcinomas patients in the MSKCC cohort (hazard ratio [HR] = 0.519, 95% confidence interval [CI] = 0.301– 0.896; P < 0.05). Conclusion: PIK3CA co-occurring mutations in other genes may represent distinct subsets of NSCLC. Further elucidation of the roles of PIK3CA hotspot mutations combined with other driver mutations, including EGFR and KRAS, is needed to guide effective treatment in patients with advanced NSCLC.Keywords
This publication has 27 references indexed in Scilit:
- Genomic mapping of metastatic organotropism in lung adenocarcinomaCancer Cell, 2023
- Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategySeminars in Cancer Biology, 2022
- Targeting KRAS in non-small-cell lung cancer: recent progress and new approachesAnnals of Oncology, 2021
- Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomesLung Cancer, 2019
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline TestingJAMA, 2017
- The PI3K Pathway in Human DiseaseCell, 2017
- Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomasNature Genetics, 2016
- PI3K signalling: the path to discovery and understandingNature Reviews Molecular Cell Biology, 2012
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human CancerCancer Cell, 2009